{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-100527","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.383676+00:00","generated_at":"2026-05-29T22:02:13.659471+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"InMed publishes study on cannabinol anti-inflammatory effects in skin diseases","bullets":["Study published in peer-reviewed journal Biofactors; sponsored by InMed and led by Dr. Maccarrone.","CBN prevented keratinocyte inflammation via TRPV1 and modulated endocannabinoid system enzymes.","CBN reduced pro-inflammatory cytokines (IL-8, IL-12, IL-31) and increased anti-inflammatory IL-10.","Potential applications for psoriasis, atopic dermatitis, and pruritus; supports cosmetic and therapeutic use."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-100527","json":"https://secwatch.observer/filing/0001213900-24-100527.json","markdown":"https://secwatch.observer/filing/0001213900-24-100527.md","text":"https://secwatch.observer/filing/0001213900-24-100527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024100527/0001213900-24-100527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024100527/ea0222020-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:02:13.659471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}